Supernus Pharmaceuticals (SUPN) Total Current Liabilities (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Total Current Liabilities of $347.4 million for Q2 2026, up 21.31% year-over-year from $286.4 million in Q2 2025, and down 7.1% on a QoQ basis from $373.9 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Total Current Liabilities (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Total Current Liabilities for 16 years, with the latest figure at $347.4 million in Q2 2026.
- Total Current Liabilities for Q2 2026 came in at $347.4 million, up 21.31% year-over-year; the trailing twelve-month figure through Jun 2026 was $347.4 million (up 21.31% YoY), and the FY2025 annual result was $338.2 million, up 15.65% from the prior year.
- Total Current Liabilities slipped to $347.4 million in Q2 2026, from $373.9 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $735.5 million in Q2 2022 and troughed at $252.6 million in Q2 2023.
- A 5-year average of $397.8 million and a median of $311.6 million in 2024 frame the typical range for Total Current Liabilities.
- The widest annual swing landed in 2022, when Total Current Liabilities surged 209.31%; it then plunged 65.66% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $688.0 million in 2022, then plunged by 57.82% to $290.2 million in 2023, then climbed by 0.76% to $292.4 million in 2024, then grew by 15.65% to $338.2 million in 2025, then climbed by 2.72% to $347.4 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $347.4 million in Q2 2026, $373.9 million in Q1 2026, and $338.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 347.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 347.38 Mn |
| Mar 31, 2026 | 373.93 Mn |
| Dec 31, 2025 | 338.17 Mn |
| Sep 30, 2025 | 330.63 Mn |
| Jun 30, 2025 | 286.36 Mn |
| Mar 31, 2025 | 281.77 Mn |
| Dec 31, 2024 | 292.40 Mn |
| Sep 30, 2024 | 291.51 Mn |
| Jun 30, 2024 | 308.66 Mn |
| Mar 31, 2024 | 314.55 Mn |
| Dec 31, 2023 | 290.20 Mn |
| Sep 30, 2023 | 287.53 Mn |
| Jun 30, 2023 | 252.59 Mn |
| Mar 31, 2023 | 731.55 Mn |
| Dec 31, 2022 | 687.96 Mn |
| Sep 30, 2022 | 725.99 Mn |
| Jun 30, 2022 | 735.54 Mn |
| Mar 31, 2022 | 284.56 Mn |
| Dec 31, 2021 | 315.38 Mn |
| Sep 30, 2021 | 234.71 Mn |